IL134748A0 - Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders - Google Patents

Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders

Info

Publication number
IL134748A0
IL134748A0 IL13474898A IL13474898A IL134748A0 IL 134748 A0 IL134748 A0 IL 134748A0 IL 13474898 A IL13474898 A IL 13474898A IL 13474898 A IL13474898 A IL 13474898A IL 134748 A0 IL134748 A0 IL 134748A0
Authority
IL
Israel
Prior art keywords
antagonists
stress
crh
pyrimidines
heterocyclyl
Prior art date
Application number
IL13474898A
Other languages
English (en)
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of IL134748A0 publication Critical patent/IL134748A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13474898A 1997-09-02 1998-09-01 Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders IL134748A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5743297P 1997-09-02 1997-09-02
PCT/US1998/018080 WO1999011643A1 (en) 1997-09-02 1998-09-01 Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders

Publications (1)

Publication Number Publication Date
IL134748A0 true IL134748A0 (en) 2001-04-30

Family

ID=22010535

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13474898A IL134748A0 (en) 1997-09-02 1998-09-01 Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders

Country Status (11)

Country Link
US (2) US6245769B1 (xx)
EP (1) EP1012151B1 (xx)
JP (1) JP2001514260A (xx)
CN (1) CN1278819A (xx)
AT (1) ATE221886T1 (xx)
AU (1) AU9041198A (xx)
BR (1) BR9814458A (xx)
CA (1) CA2303280A1 (xx)
DE (1) DE69807085D1 (xx)
IL (1) IL134748A0 (xx)
WO (1) WO1999011643A1 (xx)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
ES2258479T3 (es) 1999-10-01 2006-09-01 JOHNSON & JOHNSON CONSUMER COMPANIES, INC. Tecnica que permite calmar a las personas con la ayuda de composiciones de tratamientos personales.
EP1301511A2 (en) * 2000-07-14 2003-04-16 Bristol-Myers Squibb Pharma Company IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
US20020151527A1 (en) * 2000-12-20 2002-10-17 Benjamin Wiegand Method for reducing acne or improving skin tone
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
BR0208357A (pt) 2001-03-13 2004-06-29 Bristol Myers Squibb Pharma Co Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto
SK13752003A3 (en) * 2001-05-14 2004-11-03 Bristol Myers Squibb Pharma Co Substituted pyrazinones, pyridines and pyrimidines as ligands of factor releasing corticotropine
EP1395591B1 (en) 2001-06-12 2008-06-04 Glaxo Group Limited Corticotropin releasing factor antagonists
WO2003002105A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating bone loss
EP1401413B1 (en) 2001-06-29 2006-11-22 AB Science Use of tyrosine kinase inhibitions for treating allergic diseases
ATE330608T1 (de) 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
ATE343415T1 (de) 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
CA2452368A1 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
AU2002354575A1 (en) 2001-07-12 2003-01-29 Bristol-Myers Squibb Pharma Company Tetrahydropurinones as corticotropin releasing factor
EP1433480B1 (en) * 2001-07-13 2011-01-05 BTG INTERNATIONAL LIMITED (Company No. 2664412) Medicine containing pyrimidine derivative
US7276526B2 (en) 2001-07-13 2007-10-02 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
AU2002340405A1 (en) 2001-11-20 2003-06-10 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
GB2384563A (en) * 2002-01-29 2003-07-30 Johnson & Johnson Consumer Method of measuring the stress or relaxation level of a mammal
GB0203045D0 (en) * 2002-02-08 2002-03-27 Johnson & Johnson Consumer Method of afefecting sleep and sleep-related behaviours
US20040175438A1 (en) * 2003-03-03 2004-09-09 Benjamin Wiegand Methods for alleviating symptoms associated with menopause using sensory regimen
AU2004274403A1 (en) * 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
EP1814885A4 (en) * 2004-11-23 2009-12-16 Us Therapeutics Inc Reddy NOVEL HETEROCYCLIC BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
WO2006086464A2 (en) * 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
PL1888548T3 (pl) 2005-05-26 2013-01-31 Neuron Systems Inc Pochodna chinoliny do leczenia schorzeń siatkówki
AU2006275694A1 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
JP5608099B2 (ja) * 2008-01-30 2014-10-15 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
JP5689069B2 (ja) 2008-11-20 2015-03-25 ジェネンテック， インコーポレイテッド ピラゾロピリジンｐｉ３ｋ阻害剤化合物及び使用方法
EP2493889B1 (en) 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
WO2011082267A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrazine compounds
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
EP2863909B1 (en) 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
MX362197B (es) 2012-07-09 2019-01-08 Janssen Pharmaceutica Nv Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
HUE041760T2 (hu) 2013-09-06 2019-05-28 Hoffmann La Roche Triazolo[4,5-d]pirimidin-származékok mint CBb2-receptor antagonisták
KR102220260B1 (ko) * 2015-02-18 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘
BR112018003250A2 (pt) 2015-08-21 2018-09-25 Aldeyra Therapeutics Inc compostos deuterados e usos dos mesmos
CA3077362A1 (en) * 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
TWI701251B (zh) * 2018-02-06 2020-08-11 大陸商江蘇恒瑞醫藥股份有限公司 吡唑并[1,5-a][1,3,5]三-2-胺類衍生物、其製備方法及其在醫藥上的應用
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP7505786B2 (ja) 2018-09-25 2024-06-25 アルデイラ セラピューティクス， インコーポレイテッド ドライアイ疾患を処置するための製剤
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN112592346B (zh) * 2019-07-30 2022-04-26 厦门宝太生物科技股份有限公司 一种a2a和/或a2b抑制剂中间体的制备方法
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. PHARMACEUTICAL FORMULATIONS AND USES THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643903A1 (fr) * 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
US5378700A (en) * 1989-10-11 1995-01-03 Teijin Limited Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient
IT227968Y1 (it) 1992-11-17 1998-01-21 Moris Baroni Ago per endovene e prelievi di forma estensibile, autoinglobante per evitare punture e contagi a persone e ambienti dopo l'uso
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
CN1149870A (zh) 1994-06-06 1997-05-14 辉瑞大药厂 具有促皮质激素释放因子拮抗剂活性的取代的吡唑
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
PL181895B1 (pl) * 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
SK72996A3 (en) * 1995-06-07 1997-04-09 Pfizer Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base
DE69628804T2 (de) 1995-12-08 2003-12-18 Pfizer Inc., New York Substitutierte heterozyclische Derivate als CRF Antagonisten
WO1997027199A1 (en) * 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof

Also Published As

Publication number Publication date
EP1012151A1 (en) 2000-06-28
JP2001514260A (ja) 2001-09-11
CN1278819A (zh) 2001-01-03
US20010025042A1 (en) 2001-09-27
CA2303280A1 (en) 1999-03-11
AU9041198A (en) 1999-03-22
ATE221886T1 (de) 2002-08-15
BR9814458A (pt) 2001-10-23
WO1999011643A1 (en) 1999-03-11
US6245769B1 (en) 2001-06-12
DE69807085D1 (de) 2002-09-12
EP1012151B1 (en) 2002-08-07
US6525056B2 (en) 2003-02-25

Similar Documents

Publication Publication Date Title
IL134748A0 (en) Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
MY132871A (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
IL137019A0 (en) Azolo triazines and pyrimidines
AU4270297A (en) Pyrazinones and triazinones and their derivatives thereof
LV12262A (lv) Ar arilaminu kondenseti piridini un pirimidini
LV12292A (lv) Triazinu un pirimidinu azoloatvasinajumi
IL127170A0 (en) Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
MXPA03010324A (es) PIRAZINONAS, PIRIDINAS Y PIRIMIDINAS SUBSTITUIDAS COMO LIGANDOS DEL FACTOR DE LIBERACIoN DE CORTICOTROPINA.
CA2150016A1 (en) Pyrrolopyrimidines as CRF Antagonists
MY146935A (en) 4-(2-BUTYLAMINO-2, 7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-yl) PYRAZOLO-[1,5-a]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS
WO2002004453A3 (en) PYRROLO[3,4-d]PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
PT1140929E (pt) 1h-imidazo¬4,5-d|piridazin-7-onas 3h-imidazo¬4,5-c|piridin-4-onas e as tionas correspondentes como ligandos receptores do factor de libertacao de corticotrofina (flc)
WO2005051954A3 (en) PROCESSES FOR THE PREPARATION OF PYRAZOLO[1,5-a]-1,3,5-TRIAZINES AND INTERMEDIATES THEREOF
MY141752A (en) Pyrazolotriazines as crf antagonists
IL103440A0 (en) Heterocyclic compounds and their preparation and use
EP1380298A3 (en) Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, anorexia, inflammation